UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference
UNITY Biotechnology (NASDAQ: UBX) announced its participation in the Goldman Sachs 41st Annual Global Healthcare Conference, scheduled for June 11, 2020, at 3:50 PM E.T. The event will be held virtually, and a live audio webcast will be available on UNITY's website, with an archived replay accessible for 90 days.
UNITY focuses on developing therapeutics to extend healthspan by targeting cellular senescence, a key driver of age-related diseases. Their senolytic medicines aim to eliminate senescent cells, potentially slowing or reversing conditions like osteoarthritis.
- None.
- None.
SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the upcoming Goldman Sachs 41st Annual Global Healthcare Conference.
Goldman Sachs 41st Annual Global Healthcare Conference
Date: June 11, 2020
Fireside Chat Time: 3:50 PM E.T.
Location: Virtual
A live audio webcast of the fireside chat will be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event.
About UNITY
UNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.
Investors
Endurance Advisors
Mike Zanoni
mzanoni@enduranceadvisors.com
Media
Canale Communications
Jason Spark
jason@canalecomm.com
FAQ
When is UNITY Biotechnology participating in the Goldman Sachs 41st Annual Global Healthcare Conference?
Where can I watch the UNITY Biotechnology fireside chat?
What is the focus of UNITY Biotechnology's research?
What diseases does UNITY Biotechnology aim to impact with its therapies?
